- Home
- ECOR vs CUE Comparison
ECOR vs CUE Comparison
Compare ECOR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- CUE
- Stock Information
- Founded
- ECOR 2005
- CUE 2014
- Country
- ECOR United States
- CUE United States
- Employees
- ECOR N/A
- CUE N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ECOR Health Care
- CUE Health Care
- Exchange
- ECOR Nasdaq
- CUE Nasdaq
- Market Cap
- ECOR 50.1M
- CUE 58.9M
- IPO Year
- ECOR 2018
- CUE 2018
- Fundamental
- Price
- ECOR $5.04
- CUE $0.64
- Analyst Decision
- ECOR Strong Buy
- CUE Strong Buy
- Analyst Count
- ECOR 2
- CUE 3
- Target Price
- ECOR $25.50
- CUE $3.00
- AVG Volume (30 Days)
- ECOR 182.1K
- CUE 163.7K
- Earning Date
- ECOR 05-07-2025
- CUE 05-12-2025
- Dividend Yield
- ECOR N/A
- CUE N/A
- EPS Growth
- ECOR N/A
- CUE N/A
- EPS
- ECOR N/A
- CUE N/A
- Revenue
- ECOR $26,458,000.00
- CUE $7,991,000.00
- Revenue This Year
- ECOR $26.76
- CUE N/A
- Revenue Next Year
- ECOR $44.87
- CUE $25.99
- P/E Ratio
- ECOR N/A
- CUE N/A
- Revenue Growth
- ECOR 41.54
- CUE 13.83
- 52 Week Low
- ECOR $4.47
- CUE $0.45
- 52 Week High
- ECOR $19.49
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ECOR 39.64
- CUE 37.72
- Support Level
- ECOR $4.77
- CUE $0.61
- Resistance Level
- ECOR $5.49
- CUE $0.71
- Average True Range (ATR)
- ECOR 0.44
- CUE 0.06
- MACD
- ECOR 0.08
- CUE -0.00
- Stochastic Oscillator
- ECOR 41.08
- CUE 17.84
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.